1	Effect of background therapy with Non-
2	steroidal anti-inflammatory drugs (NSAIDs)
3	and other anti-inflammatory agents on
4	COVID-19 outcomes
5	
6	
7	Lucio Miele ^{1*} , San Chu ^{2,3} , William Hillegass ⁴ , Claudine Jurkovitz ⁵ , William Beasley ⁶ , David Chen ⁵ ,
8	A Jerrod Anzalone ⁷ , Daniel Fort ⁸ , John Kirwan ² , Brian Melancon ² , Sally Hodder ⁹ , Ronald
9	Horswell ² , on behalf of the National COVID Cohort Collaborative Consortium [^]
10	
11	¹ Department of Genetics, Louisiana State University Health Sciences Center, New Orleans,
12	LA; Louisiana Center and Translational Science (LA Cars) Center, Baton Rouge, LA.
13 17	Pennington Biomedical Research Centre, Baton Rouge, Louisiana; LA Cars Center, Baton
15	³ Louisiana State University Baton Rouge Louisiana: LA CaTS Center, Baton Rouge, LA
16	⁴ Departments of Data Science and Medicine. Mississippi Center for Clinical and
17	Translational Research, University of Mississippi Medical Center, Jackson, MS.
18	⁵ Institute for Research in Equity and Community Health (iREACH), ChristianaCare Health
19	Services, Inc., Wilmington, DE.
20	⁶ Biomedical and Behavioral Methodology Core, University of Oklahoma, Norman, OK;
21	Oklahoma Clinical and Translational Science Institute, Oklahoma City, OK.
22	⁷ Department of Neurological Sciences, College of Medicine, University of Nebraska Medical
23	Center, Omaha, NE; Great Plains IDeA-CTR, Omaha, NE.
24 25	Orleans 1A: Louisiana Center and Translational Science (LA CaTS) Center, Baton Bouge 1A
26	⁹ West Virginia University School of Medicine, Morgantown, WV: West Virginia Clinical and
27	Translational Sciences Institute. Morgantown, WV.
28	
29	Corresponding Author:
30	E-mail <u>lmiele@lsuhsc.edu (LM)</u>
31	
32	^Membership of the National COVID Cohort Collaborative Consortium is provided in the
33	Acknowledgments

35 Abstract

36	Background: Inflammation plays a complex, incompletely understood role in the
37	pathogenesis of acute COVID-19 and Post-Acute Sequelae of SARS-CoV-2 infection (PASC or
38	"Long COVID"). Systemic acute inflammation resulting in cytokine storm, hypercoagulability and
39	endothelial damage is thought to be a central mechanism for severe morbidity and mortality in
40	acute COVID-19. Anti-inflammatory medications taken routinely for chronic conditions prior to
41	contracting COVID-19 ("background medications") may modulate acute COVID-19 outcomes.
42	Methods: Using data from the National COVID Cohort Collaborative (N3C) enclave, we
43	estimated effects of six classes of background medications on acute COVID outcomes.
44	Medication classes included aspirin, celecoxib, other NSAIDS, steroids, immune suppressants,
45	and antidepressants. Acute COVID outcomes included probability of hospital admission,
46	inpatient mortality, and mortality among diagnosed COVID patients. Each medication class was
47	compared to benzodiazepines (excluding midazolam) which served as a comparator/control.
48	Only adult COVID patients with pre-existing osteoarthritis and without any diagnosed
49	autoimmune disease were included in the analyses. Random effects logistic regression models
50	were used to adjust for covariates and data contributing organization. Medication effects also
51	were estimated for COVID-negative cases.
52	Results: Non-aspirin NSAIDS were associated with lower mortality among diagnosed
53	COVID-19 patients: adjusted Odds Ratio (aOR)=0.32 (p=.032) for celecoxib; aOR=0.51 (p<.001)
54	for NSAIDS other than aspirin and celecoxib. For inpatient mortality: aOR=0.34 (p=.060) for
55	celecoxib and aOR=0.74 (p=.200) for other non-aspirin NSAIDS. Similar effects were observed
56	for COVID-negative cases, including for inpatient mortality: aOR=0.21 (p<.001) for celecoxib and

aOR=0.34 (p<.001) for other non-aspirin NSAIDS. Secondary analyses examined alternative
explanations for results.

59	Discussion: Protective effects were observed for non-aspirin NSAIDS, especially
60	celecoxib. However, those estimated effects implicitly assume the medication classes did not
61	differ on the probability a true COVID-19 case was diagnosed. The similarity of COVID-positive
62	and COVID-negative results suggest possible missing covariates. However, such similarity
63	plausibly could stem from a medication having both "direct" and "indirect" effects on COVID
64	outcomes. Adjudicating among the alternative interpretations would require data beyond those
65	available. However, the effects observed for non-aspirin NSAIDS, while possibly biased,
66	rationalize further investigation using study designs constructed to overcome the limitations of
67	existing datasets.
68	Keywords: Anti-inflammatory, NSAIDs, celecoxib, aspirin, immune suppressant, steroid,
69	antidepressant, benzodiazepine, COVID19, NC3.
70	
71	

73 1. Introduction

Inflammation plays a complex and incompletely understood role in the pathogenesis of acute 74 75 COVID-19 [1-4] and Post-Acute Sequelae of SARS-CoV-2 infection (PASC or "Long COVID") [5]. 76 Systemic acute inflammation resulting in cytokine storm, hypercoagulability and endothelial 77 damage is thought to be a central mechanism for severe morbidity and mortality in acute 78 COVID-19 [1-4]. 79 Several classes of anti-inflammatory agents have been proposed as COVID-19 treatments. A 80 meta-analysis of 7 randomized controlled trials (RCT) showed that corticosteroids 81 (dexamethasone, hydrocortisone or methylprednisolone) decrease mortality when used to 82 treat critically ill COVID-19 patients [6]. 83 Non-steroidal anti-inflammatory drugs (NSAIDs) have been considered potentially unsafe in 84 COVID-19 [7] due to their cardiovascular and renal side effects and the potential to decrease 85 anti-viral responses [7], though very little information is available on their safety in COVID-19 86 patients [8]. At least two selective serotonin re-uptake inhibitors (SSRIs), fluvoxamine and 87 sertraline, were suggested to be effective as adjunctive therapy for COVID-19 based on their 88 anti-inflammatory effects [9]. 89 The anti-inflammatory agents of interest here were used not as therapy for acute events but 90 rather as "background medications" (i.e., medications taken routinely for chronic conditions). 91 Here we examine the possible effects on COVID outcomes of several background medication 92 groups, all of which have anti-inflammatory activity. 93 Using the National COVID Collaborative Cohort (N3C) database [10], Reese et. al. [11] focused

94 on analyzing the effect of NSAIDs (including celecoxib, diclofenac, droxicam, etodolac,

95 ketorolac, ibuprofen, indomethacin, lornoxicam, meloxicam, naproxen, piroxicam, tenoxicam) 96 on patients with hospital admissions for COVID-19, finding a statistically significant relationship 97 between NSAIDs use prior to admission and inpatient mortality (odds ratio = 0.51), but noted 98 the potential vulnerability of that estimate to missing covariates. 99 The research question that our analyses seek to address is: Is there an association between 100 background chronic treatment with anti-inflammatory medications and COVID-19 outcomes? 101 To address that question, we conducted analyses using N3C data, as described below, for 102 osteoarthritis patients who did not have concomitant autoimmune disorders, as these patients 103 are most likely to be taking prescription anti-inflammatory agents and are not subject to the 104 possible confounding effects of autoimmune disorders. Within the osteoarthritis group, we also 105 considered patients taking immune-suppressant medications (e.g., transplant recipients) and 106 patients taking SSRIs or systemic, oral steroids, based on the literature on these agents in 107 COVID-19. 108 The estimation of background medication treatment effects is challenging for several reasons, 109 leading to estimated treatment effects whose interpretation is ambiguous. Much of this paper 110 is devoted to development of strategies to help clarify interpretation of estimated medication 111 effects. 112 The analyses and results described in this paper were generated by using the National Institutes 113 of Health's National COVID Cohort Collaborative (N3C) database. N3C is a centralized, secure 114 harmonized electronic health record database containing U.S. nationwide COVID-19-related 115 data. As of April 2023, the N3C database included data from 74 data partner (DP) healthcare

116 organizations. Each DP has contributed data for two types of individuals: (1) Individuals with at

- 117 least one positive COVID-19 test result or provider diagnosis (here called "COVID-positive"
- 118 patients), and (2) individuals who were tested for COVID-19 one or more times but with no
- 119 positive test results on record (called "COVID-negative" patients).

120 2. Methods

- 121 **2.1.** *Eligibility*
- 122 Each DP contributed clinical data for all its identified COVID-19 positive cases. Each DP also
- 123 contributed a sample of its COVID-19 negative cases, with that sample generated by matching
- to COVID-19 positive cases on age, gender, race, and ethnicity using a positive-to-negative
- 125 matching ratio of 1:2. The N3C data were first made available for research in August 2020 and
- 126 have been subsequently updated weekly. The data sent to N3C by each DP include
- 127 demographics, symptoms, lab test results, diagnoses, procedures, medications, medical
- 128 conditions, physical measurements. Of the 74 DPs contributing data to N3C, data contributions
- 129 from 70 DPs were of potential use. As of February 12, 2022 (the date of data extraction for this
- project) those 70 DPs had contributed data for 12,093,403 patients. Data from 70 of the 74 DPs
- 131 were used. The four excluded DPs' data could not be used, as those DPs' data lacked explicit
- dates of events (e.g., outcomes events) that the analysis required.
- 133 The diagram in Fig 1 summarizes how an ultimate group of 485,779 osteoarthritis patients was
- selected from those 12,093,403 patients. To avoid the possible confounding effects of
- 135 vaccination on COVID outcomes, only data covering events during the time span 01/01/2020
- through 03/31/2021 (i.e., before widespread vaccination implementation) were used. To assure
- 137 the cohort included only patients with well-documented clinical histories, only adult patients

138 with outpatient visits spanning 30+ days and prescription information spanning 30+ days were

- 139 considered potentially eligible.
- 140 Figure 1: Selection of patients meeting eligibility criteria.
- 141 Some of the N3C DPs do not have inpatient facilities, and their data contributions include little
- 142 (inpatient COVID-19 rate ≤ 0.001) or no inpatient data. Therefore, data from four (of 74) DP
- 143 organizations were excluded, because the outcomes measures used in our analyses cannot be
- 144 defined without use of inpatient information. Exclusions for age <35 and for missing
- 145 demographic information left 2,396,594 individuals eligible before clinical exclusions.
- 146 To achieve a more nearly clinically homogenous cohort of patients, but a cohort with
- 147 substantial use of anti-inflammatory agents, eligibility was further restricted to patients with
- 148 diagnosed osteoarthritis but without autoimmune disease. Specifically excluded for
- autoimmune disease were those diagnosed with rheumatoid arthritis, lupus, juvenile
- 150 rheumatoid arthritis, inflammatory bowel disease, as well as certain other less prevalent
- 151 autoimmune disorders. Further, regardless of diagnosis codes present, any patients using
- 152 medications strongly associated with autoimmune disease treatment were excluded. The
- 153 medications whose use led to exclusion included DMARDs, Methotrexate, cytokine-targeted
- biologics, non-anti-inflammatory biologics, and anti-allergy biologics.
- 155 The above inclusion/exclusion criteria led to a final group of 485,779 osteoarthritis patients, of
- 156 which 140,260 were "COVID-positive" and 345,519 were "COVID-negative."

157 **2.2.** Background medication (treatment) groups

- 158 The anti-inflammatory medications considered represent six distinct medication groupings
- 159 groups, as shown in Table 1. In addition, a seventh medication group (benzodiazepine

- sedatives) was defined to serve as a control group. Benzodiazepines were selected because to
 our knowledge they lack clinically meaningful anti-inflammatory or anti-viral effects. As
 depicted by the solid arrows in Fig 2, the analyses described here compare each of the six antiinflammatory medication groups to the control group. Inclusion in a medication group required
 evidence (in the form of a prescription date) that the medication was used both within the 30
 days prior to COVID-19 diagnosis and also more than 30 days prior to the COVID-19 diagnosis.
- 166 Table 1: Background Medication Groups

Medication group	Descriptions
Non-specific NSAIDs	Non-steroidal anti-inflammatory drugs (excludes celecoxib and
	aspirin)
Celecoxib	Celecoxib was considered individually due to its selectivity for
	COX-2 as opposed to other prescription NSAIDs
Aspirin	Aspirin was considered individually as it is often prescribed for
	its anti-platelet activity to patients at significant risk for
	cardiovascular or cerebrovascular disease.
Immune suppressants	Small-molecule, non-steroid immune suppressants often
	prescribed to prevent rejection in transplant recipients were
	included due to their potential suppressive effects on anti-viral
	immunity.
Steroids	Steroids were included due to their potential suppressive
	effects on anti-viral immunity.

Antidepressants	Antidepressants (SSRIs and tricyclic medications) have anti-		
	inflammatory properties and can be prescribed for		
	osteoarthritic pain.		
Benzodiazepine sedatives	(This group serves as a comparator /control group.)		
(excluding midazolam)	As a small-molecule control class, we selected benzodiazepine		
	sedatives. These are prescribed as anxiolytics or hypnotics. To		
	our knowledge, this class of medications has no known		
	clinically significant anti-inflammatory or anti-viral effects.		

167

168 Figure 2: Pairwise Comparisons used in the Primary Analyses.

169 **2.3.** *Primary analyses*

170 Each of the six pairings with the control medication group shown in Fig 2 led to six distinct

171 statistical models, which estimated six comparison measures which for convenience we refer to

as M1, M2, M3, M4, M5, and M6. After adjustment for demographics and known comorbidities,

173 three of the measures compare outcomes among COVID-positive patients, and three compare

174 outcomes among COVID-negative patients. Specifically, the COVID-positive measures are:

- 175 **M1** = the adjusted odds ratio (aOR) comparing **90-day death rates**, defined as death or
- 176 discharge to hospice within the 90 days following the first date on which the subject was
- 177 known to be COVID-positive.
- 178 **M2** = the adjusted odds ratio comparing **90-day admission rates**, defined as a hospital
- admission within the 90 days following the first date on which the subject was known to
- 180 be COVID-positive.

181	M3 = the adj	justed odds ration	o comparing c	death rate among	hospitalized	patients,	defined as
-----	--------------	--------------------	----------------------	------------------	--------------	-----------	------------

- death or discharge to hospice within the 90 days following a hospital admission, with
- 183 that admission required to have occurred within +/- seven days of the subject's first
- 184 known COVID-positive date.
- 185 The three corresponding measures for COVID-negative patients are:
- 186 M4 = the adjusted odds ratio comparing 90-day death rates, defined as death or discharge to
- 187 hospice within the 90 days following an encounter date randomly selected from the
- 188 subject's encounters.
- 189 **M5** = the adjusted odds ratio comparing **90-day admission rates**, defined as a hospital
- admission within the 90 days following an encounter date randomly selected from thesubject's encounters.
- 192 **M6** = the adjusted odds ratio comparing **death among hospitalized patients**, defined as death
- 193 or discharge to hospice within 90 days of a hospital admission, with the hospital

admission randomly selected from among the subject's hospitalizations.

195 Because many patients use multiple medications, each of the above six comparison measures

196 was estimated using the exclusion logic depicted in Fig 3. For example, when comparing aspirin

- users to benzodiazepine users (the control medication group), those using both of those
- 198 medications were excluded. Also excluded were those using any of the other Table 1

199 medications.

200 Figure 3: Medication-related Inclusion/Exclusion Logic for Pairwise Comparisons.

201 We also conducted direct outcomes comparisons for all the other pair-wise comparisons of

202 medication groups, such as the comparison between celecoxib and aspirin. Those results

Logistic regression mixed models were used to estimate M1, M2, M3, M4, M5, and M6 for each

appear in the S1 Supplemental Material. Those modeling results, however, are strongly
transitive. For example, the result of comparing celecoxib and aspirin can be derived with
considerable accuracy from the comparisons of celecoxib to the control and aspirin to the
control.

207

208 of the medication group comparisons defined in Fig 2 (a total of 36 models). In each of those 209 models, the medication effect was defined as a binary treatment variable (e.g., celecoxib versus 210 the control group, aspirin versus the control group, etc.). Covariates used in the models 211 included rurality (rural, urban), gender (female, male), race (black, white, and other), ethnicity 212 (Hispanic, non- Hispanic), age group (35-44, 45-54, 55-64, 65-74, and 75+), and Charlson 213 Comorbidity Index [12] score (range 0 to 31), and subjects are nested within DP, and DP was 214 incorporated into the models as a random effect. Because age was a covariate in the model, it 215 was adjusted from the Charlson Comorbidity Index formula for this project as follow: CCI Index

216 = mi+ chf + pvd + stroke + dementia + pulmonary + rheumatic + pud + livermild +

dm + 2*dmcx + 2*paralysis+ 2*renal + 2*cancer + 3*liverSevere + 6*mets +6*hiv. Each single
disease's contribution to this formula was also tested with stepwise logistic regression models
and have no single significant effect.

Fig 4 summarizes the eligibility logic underlying the statistical modeling. Eligibility required at least one outpatient clinic visit and at least one medication prescription over a time span that ended 30 days prior to the subject's reference date. As shown in Fig 4, we distinguished between (a) background medication use within 30 days prior to a subject's reference date and (b) background medication use earlier than 30 days prior to the reference date. For analysis

- 225 purposes, background medication group (e.g., aspirin users) included only those with evidence
- of background medication usage in both of those time spans (e.g., aspirin prescriptions in both
- 227 time spans.)
- 228 Figure 4: Medication Comparisons Analysis Logic.
- 229 **2.4. Secondary Analyses**
- 230 Our secondary analyses are included to help clarify interpretation of the primary analysis
- results. In particular, the secondary analyses attempt to address, at least to some extent, two
- 232 interpretation questions:
- 233 Question 1: Do background medication effects estimated using data from only diagnosed
- 234 COVID cases logically reflect the true effects of the medications?
- 235 Question 2: Do the primary analyses medication effects, estimated as comparisons to the
- 236 control medication group, reflect effects actually generated by the background
- 237 medications; or do those estimated effects simply reflect unknown risk differences that
- 238 where among the factors originally determining background medication choices?
- As described below, Question #1 and #2 above, both reflecting interpretation ambiguities, arise
- for two main reasons: (1) the fact that the background medication user groups were formed, by
- 241 definition, prior to exposure to COVID, and (2) the possibility that the medication user groups
- 242 differ systematically on unknown risk factors.

243 <u>2.4.1. Assessing for Possible Confounding due to Pre-existing Treatment Groups</u>

The medication groups compared were implicitly formed prior to the subjects' development of
COVID. Therefore, it is plausible that the medications may have differentially affected the
severity of COVID illness prior to diagnosis, leading to possible differences in the probability

that an active COVID case was diagnosed. As described below, the result can be interpretationambiguity.

249 Here we refer to a target medication of interest (e.g., aspirin) as the "Medication A" cohort, and 250 the control medication users as the "Medication B" cohort. Fig 5 conceptually depicts the 251 nested Medication A patient groups that are involved (either implicitly or explicitly) in our 252 primary analyses. The full A1 ellipse represents the full cohort of background medication A 253 users who meet the Fig 4 eligibility criteria, including those whose data are not on the N3C 254 enclave, because they were never diagnosed. The A2 ellipse represents those who contracted 255 COVID. A3 represents those who were diagnosed with COVID-19. A4 represents those who had 256 hospital admissions due to COVID-19. And, finally, A5 represents those Medication A users who 257 died within 90 days of COVID diagnosis. Note that, while not shown in the figure, there are 258 analogous groups (B1, B2, B3, B4, and B5) for Medication B users (the control group.) The 259 COVID-positive cases represented on the N3C enclave for Medication A include only those in A3 260 (which also implicitly includes A4 and A5). Among the Medication B cohort, the N3C enclave 261 includes only those in B3 (which includes B4 and B5.) 262 Figure 5: Conceptual Diagram of Nested Groups within the COVID Positive Treatment 263 **Medication Cohort.** 264 Our primary analysis measure M1 compares the Medication A and B groups on mortality among 265 diagnosed COVID cases. The relative risk (RR) version of M1 in terms of the Fig 5 the nested 266 patient groups is: $M1_{RR} = RR(90\text{-day mortality}|COVID diagnosis})_{A/B} = \frac{P(A5|A3)}{P(B5|B3)} = \frac{N_{A5}/N_{A3}}{N_{R5}/N_{R3}}$ 267 (Equation 1)

268 (Note: Relative Risk measures are used here, because the mathematical rationale for our

- 269 secondary analyses is more efficiently described in relative risk terms.)
- 270 M1_{RR} (and M1) ignore any possible medication group difference in the probability of being
- diagnosed with COVID. In terms of Fig 5, M1_{RR} (and M1) use only the cases falling within the A3

and B3 sets. By contrast, a measure M7_{RR} comparing medication cohorts on full-cohort

273 mortality would compare values of P(A5|A1) and P(B5|B1); that is:

274 (Equation 2) $M7_{RR} = RR(90\text{-day mortality})_{A/B} = \frac{P(A5|A1)}{P(B5|B1)} = \frac{N_{A5}/N_{A1}}{N_{B5}/N_{B1}} = \left(\frac{N_{A5}}{N_{B5}}\right)\left(\frac{N_{B1}}{N_{A1}}\right)$

275 M7_{RR} also has interpretation problems; for example, it could be distorted by medication group

differences in the probability of contracting COVID. However, **if it could be determined that**

277 $M1_{RR} \approx M7_{RR}$ holds, that would strongly suggest (albeit not conclusively prove) that pre-

278 diagnosis medication effects are not distorting the medication comparison and, therefore,

279 M1_{RR} (and its adjusted odds ratio form M1) is a valid comparison of medication effects on

280 COVID mortality, and is unlikely to be meaningfully distorted by medication differences in the281 probability of COVID diagnosis.

282 But measure M7_{RR} cannot be estimated directly, because NB1 and NA1 cannot be directly

283 calculated from COVID-positive N3C data. However, estimating $M7_{RR}$ does not necessarily

require an ability to estimate N_{A1} and N_{B1} individually. All that is required is the ability to

285 calculate the ratio N_{A1}/N_{B1}. The Supplemental Material describes an approach to estimating the

ratio N_{B1}/N_{A1} using the COVID-negative cases appearing on the N3C enclave. The results for

287 measure M7_{RR} appearing in Section 3.0 below were obtained using that method.

Note that the above describes two different mortality constructs. M1_{RR} is a comparison of 288 289 mortality among those diagnosed with COVID, while M7_{RR} is a comparison of mortality among 290 all members of a medication usage cohort. If $M1_{RR} \approx M7_{RR}$ holds, the two mortality constructs 291 are numerically very similar, in which case $M1_{RR}$ can be viewed as a good surrogate for $M7_{RR}$. 292 If $M1_{RR}$ and $M7_{RR}$ differ substantially, it might be thought that they still are both valid measures, 293 each being a measure for its own mortality constructs. That is true. However, as described in 294 the Supplementary Material, it is not clear that $M1_{RR}$ has any substantive meaning other than possibly qualifying as a surrogate for M7_{RR}. The reason is that the value of M1_{RR} alone (or M1 295 296 alone) does not of itself carry any implications regarding background medication choice. $M1_{RR}$ 297 (and M1) may show a post-diagnosis mortality advantage for background medication A. But 298 pre-diagnosis medication effects may negate or reverse that advantage.

Note that once $M7_{RR}$ is estimated as described above, the measure $M8_{RR}$, the ratio of $M7_{RR}$ to

 $M1_{RR}$, compares the two medication groups on the probability of being diagnosed with COVID:

301 (Equation 3)
$$M8_{RR} = \frac{N_{A3}/N_{A1}}{N_{B3}/N_{B1}} \approx \frac{N_{A5}/N_{A1}}{N_{B5}/N_{B1}} \div \frac{N_{A5}/N_{A3}}{N_{B5}/N_{B3}} = \frac{M7_{RR}}{M1_{RR}}$$

302 This measure also is useful in helping to clarify interpretation.

303 <u>2.4.2. Possible Distortion due to Missing Covariates</u>

Each patient in a particular background medication group (e.g., the Medication A users) is presumably in the medication group for primarily clinical reasons, although patient preference, insurance coverage, and chance are contributing factors as well. It is, therefore, quite plausible that the available data are not sufficient to fully adjust for all the clinical factors underlying medication decisions.

309	However, in discussing the effects of missing covariates, it is helpful to first describe another
310	potential COVID-related data characteristic; namely, that a medication's effect on COVID
311	outcomes may be either "indirect" or "direct." An indirect (non-COVID-specific) effect is present
312	if the target medication alters (reduces or increases) the risk of non-COVID outcomes by
313	mitigating (or exacerbating) general health risk. By contrast, a direct effect on COVID outcomes
314	is present if the target medication alters COVID outcomes risk without altering general health
315	risk.
316	As described in the Supplemental Material, the medication treatment effect in a primary
317	outcomes model (for example, the M1 effect) is a composite effect that conceptually includes:
318	a) Any effects of unknown risk factors that are orthogonal to the known risk factors
319	included in the model,
320	b) Any indirect effects of medication A, stemming from medication A affecting the levels of
321	risk factors, including both known and unknown risk factors, and
322	c) Direct effects of medication A on COVID outcomes.
323	The Supplemental Material describes two scenarios under which the "direct effects" can be
324	estimated:
325	Scenario 1: Estimate direct effects assuming there may be unknown risk factors, but there are
326	no indirect medication effects.
327	Scenario 2: Estimate direct effects assuming there may be indirect medication effects but no
328	unknown risk factors.
329	As shown in Section 3.2 below (and described in the Supplemental Material), the estimated
330	direct effect varies greatly depending on which of the above scenarios is assumed to hold, and

- 331 estimates based on the above scenarios serve to conceptually bound the influence of potential
- 332 unknown covariates and indirect medication effects. However, it must be kept in mind that the
- 333 estimation of a medication's direct effect is not fully satisfactory, because a medication's
- indirect effect also is a true medication effect.

335 2.5 Ethics Statement

- 336 N3C operates under the authority of the National Institutes of Health IRB, with Johns Hopkins
- 337 University serving as the central IRB (IRB00249128). The N3C Enclave contains de-identified,
- 338 retrospective data collected by data partners (DP) under a single IRB-approved protocol
- through IRB reliance agreements. No data can be downloaded from the N3C enclave. Analytical
- 340 code is uploaded onto the enclave, and only results can be downloaded. The study described
- 341 herein was also approved by the Pennington Biomedical Research Center's IRB (20211-016-
- 342 PBRC). The N3C Data Access Committee (RP-504BA5) approved the study "COVID-19
- 343 Treatments Associated with Lower Mortality". No informed consent was obtained from
- 344 individual patients because the study used a limited data set already stripped of direct
- identifiers in compliance with the HIPAA Privacy Rule.

346 3. Results

347 <u>3.1 Primary Analysis Results</u>

Fig 6 and Table 2 summarize the results from the primary analysis models. Non-specific NSAIDs
as a group were associated with significantly lower risks of admission in both the COVID-

350 positive and the COVID-negative cohorts and with significantly lower risk of inpatient death for

- 351 the COVID-negative but not the COVID-positive cohort. (For COVID-positive hospitalization rate
- aOR = 0.79, and for COVID-negative hospitalization rate aOR = 0.78)).

353 Figure 6: Estimate treatment effects (adjusted odds ratios) from the primary analysis.

354 Table 2: Adjusted odds ratios from the primary analysis

Measure	Med group A	aOR	95% CI	p_value
M1	NSAID	0.51	0.35, 0.74	<0.001
	Celecoxib	0.32	0.09, 0.81	0.032
	Aspirin	1.32	1.04, 1.68	0.024
	Immune suppressant	1.13	0.72, 1.75	0.6
	Steroid	1.15	0.93, 1.45	0.2
	Anti-depressant	0.93	0.72, 1.19	0.5
M2	NSAID	0.79	0.67, 0.92	0.002
	Celecoxib	0.83	0.59, 1.14	0.2
	Aspirin	1.62	1.40, 1.88	<0.001
	Immune suppressant	1.86	1.45, 2.40	<0.001
	Steroid	1.33	1.17, 1.50	<0.001
	Anti-depressant	1.1	0.96, 1.26	0.2
M3	NSAID	0.74	0.45, 1.20	0.2
	Celecoxib	0.14	0.01, 0.71	0.06
	Aspirin	1.08	0.79, 1.49	0.6
	Immune suppressant	1.15	0.68, 1.94	0.6
	Steroid	1.23	0.93, 1.66	0.2
	Anti-depressant	1.01	0.73, 1.40	>0.9
M4	NSAID	0.25	0.18, 0.34	<0.001
	Celecoxib	0.11	0.04, 0.27	<0.001

	Aspirin	0.86	0.73, 1.03	0.1
	Immune suppressant	0.37	0.22, 0.60	<0.001
	Ctoroid	0.77	0.001	0.001
	Steroid	0.77	0.66, 0.91	0.001
	Anti-depressant	0.65	0.53, 0.79	<0.001
M5	NSAID	0.78	0.71, 0.86	<0.001
	Celecoxib	0.95	0.80, 1.11	0.5
	Aspirin	1.17	1.06, 1.28	0.001
	Immune suppressant	0.92	0.75, 1.12	0.4
	Steroid	1.26	1.16, 1.36	<0.001
	Anti-depressant	0.93	0.85, 1.02	0.12
M6	NSAID	0.34	0.26, 0.43	<0.001
	Celecoxib	0.21	0.12, 0.32	<0.001
	Aspirin	0.66	0.58, 0.76	<0.001
	Immune suppressant	0.49	0.35, 0.68	<0.001
	Steroid	0.79	0.70, 0.89	<0.001
	Anti-depressant	0.67	0.58, 0.78	<0.001

355

356 Celecoxib showed no significant association for hospitalization in either for COVID-positive

hospitalization rate aOR = 0.83, or for COVID-negative hospitalization rate aOR = 0.95.

358 Conversely, aspirin was associated with significantly higher aOR of hospitalization in COVID-

positive aOR = 1.62 and to a lesser extent in COVID-negative patients aOR = 1.17.

360 Immune suppressants were associated with significantly higher aOR of hospitalization in COVID-

361 positive aOR = 1.86 but not in COVID-negative cases aOR = 0.92.

medRxiv preprint doi: https://doi.org/10.1101/2024.12.07.24318645; this version posted December 8, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

362 Background steroid treatment was associated with significantly higher aOR of hospitalization in

363 both groups, with very similar point estimates. For COVID-positive hospitalization rate, aOR =

364 1.33, and for COVID-negative hospitalization rate aOR = 1.26.

365 No significant associations were observed for antidepressants as a group. (For COVID-positive

366 hospitalization rate aOR = 1.1, and for COVID-negative hospitalization rate aOR = 0.94).

367 The medication group that showed the largest difference between COVID-positive and COVID-

368 negative cases was immune suppressants (1.86 versus 0.92, respectively), consistent with the

369 notion that patients on these medications are at higher risk for infectious complications,

including COVID-19 [12].

371 When we examined the risk of death in all comers (inpatients and outpatients), non-specific

372 NSAIDs and celecoxib were associated with significantly lower aOR of mortality in both COVID-

positive (for NSAIDs' mortality rate aOR = 0.51, and for celecoxib's mortality rate aOR = 0.32)

and COVID-negative cases (for NSAIDs' mortality rate aOR = 0.25, and for celecoxib's mortality

375 rate aOR = 0.11), while aspirin was associated with significantly higher aOR of mortality in

376 COVID-positive aOR = 1.32 but not in COVID-negative aOR = 0.86. Similarly, background steroid

377 treatment was associated with significantly higher aOR of mortality in COVID-positive aOR =

378 1.15 but not n COVID-negative cases aOR = 0.77 while antidepressants showed no significant

association with aOR of mortality in COVID-positive aOR = 0.93 and a significant negative

380 association in COVID-negative aOR= 0.65.

381 3.2 Secondary Analysis Results

382 The secondary analyses focus on the interpretation questions posed in Section 2.4. Fig 7

383 compares values of measure $M1_{RR}$ (relative risk of death given a COVID diagnosis) to values of

384	$\mathrm{M7}_{\mathrm{RR}}$ (relative risk of COVID death among all medication cohort members.) Results for the two
385	measures are quite similar for all the medications except celecoxib and the immune
386	suppressants, for which $M1_{RR}$ and $M7_{RR}$ differ approximately by a factor of two, but in different
387	directions. The implication is that the diagnosis-denominated measure, $M1_{\mbox{\tiny RR}}$, may not
388	adequately reflect the COVID mortality experience of those two medication groups. However,
389	the sample sizes for celecoxib and for immune suppressants are too small to draw any
390	confident conclusions.
391 392	Figure 7: Relative Risk of Death COVID Diagnosis and Relative Risk of Death in Medication Cohort.
393	Fig 8 shows estimates of medication direct effects under two different assumptions: an
394	assumption that some relevant covariates are unknown but there are no indirect medication
395	effects, versus the assumption that indirect medication effects may be present but there are
396	not missing risk factors. The adjusted odds ratios for our primary analysis measure M1 are
397	graphed by the solid black line. The dashed red line graphs M1 after adjustment for the
398	potential effects of unknown risk factors. The dashed blue line graphs M1 after adjustment for
399	the potential indirect medication effects. Of course, bias may be present from both unknown
400	covariates and indirect medication effects. The potential bias from indirect medication effects is
401	much less than the potential bias from unknown covariates. Further, the <u>actual</u> bias present
402	from either source may be much less than the full <u>potential</u> bias quantified in Fig 8.
403 404	Figure 8: Medication Effects after adjustment for unknown covariates of adjustment for indirect effects.
405	In Fig 8, results under an assumption of indirect medication effects seem more plausible than
406	results assuming possible missing covariates.

407 **4. Discussion**

With the interpretation caveats described above, given osteoarthritis patients who had not 408 409 been diagnosed with autoimmune disorders as a target population, background NSAIDs except 410 aspirin were associated with lower hospitalization rates as compared to the non-anti-411 inflammatory control group (sedatives). In contrast, background aspirin and systemic steroids 412 were associated with higher admission rates compared to control. 413 The results described in this study in the N3C enclave provide potentially useful information for 414 clinicians treating patients at risk for COVID-19. It is important to point out that these results do 415 not necessarily imply that pharmacological activities of the agents we studied directly affect 416 COVID-19 outcomes. This is because of the interpretation challenges described under Methods, 417 and because groups of patients identified by treatment with each of these medication classes 418 do not have identical baseline risks of hospitalization and death, nor do they have identical 419 baseline risk profiles for SARS-CoV2 infection or symptomatic COVID-19 disease. Rather, each 420 medication class can be seen as identifying a group of patients potentially at higher or lower 421 risk of hospitalization or death, and COVID-19 adds to these different baseline risk profiles. 422 Among patients with osteoarthritis, background prescription NSAIDs, either non-specific or 423 COX-2 selective, do not appear to contribute to the risk of COVID-19 hospitalization or death, 424 with the prominent exception of aspirin. Patients on background prescription aspirin appear to 425 be at higher risk of hospitalization when COVID-positive, and to a lesser extent when COVID-426 negative, and to be at significantly higher risk of non-inpatient death (presumably from acute 427 complications prior to hospitalization) when COVID-positive but not when COVID-negative. A possible explanation for this is protopathic effect, meaning that aspirin is used to treat 428

conditions that increase the risk of hospitalization and death in COVID-positive patients. Unlike 429 430 other NSAIDs, in addition to its uses as an anti-inflammatory agent, aspirin is used alone or in 431 combination with other agents as part of anti-platelet therapy to prevent thrombosis in 432 patients at risk after acute cardiovascular events or procedures, e.g. patients with percutaneous 433 coronary intervention (PCI), [13], total hip arthroplasty [14], or limb revascularization [15]. 434 Furthermore, prescription aspirin is used for the primary prevention of coronary artery disease 435 [16]. These conditions are likely to increase the baseline risk of hospitalization and sudden 436 death in COVID-positive patients. Cardiovascular disease (CVD) is a recognized risk factor for 437 COVID-19 morbidity and mortality [17]. Our data suggest that patients on chronic prescription aspirin who are still unvaccinated against currently circulating strains of SARS-CoV-2 should 438 439 consider COVID-19 vaccination and mitigate the risk of infection. 440 Our results for NSAIDs are consistent with the results obtained by Reese et al [11], 441 whose estimated effect of NSAIDs, including Celecoxib, on inpatient mortality (OR = 0.51) lies between our estimated effects for Celecoxib (OR = 0.14) and non-specific NSAIDs (OR = 0.74). 442 443 Celecoxib deserves separate consideration, as background treatment with it was associated with reduced relative risk of death in both COVID-positive and COVID-negative 444 445 patients. We do not know whether these effects are due to a hidden variable common to 446 celecoxib-treated patients or can be attributed to the medication itself. If celecoxib simply 447 masked symptoms of mild COVID-19, preventing diagnosis of such cases, one would expect the opposite effect, i.e., a higher risk of severe outcomes in celecoxib-treated patients. COX-2 448 449 inhibition had been proposed as a possible treatment for COVID-19 [18] and a small clinical trial 450 in mild or moderate COVID-19 supports this notion [19]. In that study, lymphocyte counts were

451 increased in patients taking celecoxib. Furthermore, a large real-world evidence observational 452 study by Liao [20], based on claims data from 2,935,415 unvaccinated and 189,692 vaccinated 453 patients, identified NSAIDs including celecoxib-aspirin combinations, celecoxib-ibuprofen 454 combinations and celecoxib single agent as having repurposing potential for COVID-19 455 treatment [20]. Unlike our results, aspirin was also associated with a lower risk of COVID-19 456 mortality in that study. Significant differences between the two studies are the inclusion 457 criteria, with in our study are restricted to osteoarthritis without autoimmune disorders, and 458 the fact that risk adjustment in Liao's study used a proprietary Optum Episode Risk Group Score 459 [18]. A different theoretical approach, using multi-evidence deep graph neural networks [21], 460 predicted anti-COVID-19 activities for aspirin and celecoxib. A molecular modeling study 461 identified celecoxib as a potential inhibitor of the SARS-CoV-2 main protease, thus 462 hypothesizing a direct antiviral activity [22]. Besides this putative antiviral activity, COX-2, the 463 primary target of celecoxib, is a key player in inflammation, and its major product, PGE₂, 464 suppresses T-cell-mediated cellular immunity while promoting Th2 responses [23]. It is possible 465 that COX-2 inhibition may improve immune responses to SARS-CoV-2. The apparent association 466 of background celecoxib with lower risk of mortality in COVID-negative patients is more difficult 467 to explain. Given that celecoxib is contraindicated in patients with history of cardiovascular 468 events, including myocardial infarction and PCI or other coronary revascularization, it is possible 469 that the baseline risk of cardiovascular events in patients on celecoxib may be lower than that 470 of patients on other medication groups we studied. However, the PRECISION trial results 471 showed that at currently recommended doses, the cardiovascular and renal safety profile of 472 celecoxib is favorable compared to non-specific NSAIDs ibuprofen and naproxen [24]. It's worth

473	noting that PGE_2 also suppresses tumor immunity [25, 26], some studies support the use of
474	celecoxib as an adjuvant to cancer treatment [27] and a vast literature supports the use of
475	NSAIDs [28-31], and celecoxib in particular [32] as cancer chemo-preventive agents. Initial
476	enthusiasm for selective COX-2 inhibitors was dampened by their cardiovascular side effects
477	[33]. Our data, within the limitations of the N3C dataset and the analytical strategy we used,
478	are consistent with the notion that background use of celecoxib is associated with a decreased
479	risk of all-cause mortality in COVID-negative and -positive patients. This data supports the
480	predictions made by Liao [20] and Hsieh et al. [21].
481	Background steroid medications were association with increased risk of inpatient death and
482	all-comers death in COVID-19 positive but not in COVID-19 negative patients. Despite the fact
483	that dexamethasone is effective in treating severe COVID-19, it is possible that chronic use of
484	steroids may dampen protective immunity against SARS-CoV-2.
485	Immune-suppressants (e.g. rapalogs) were associated with increased risk of hospitalization
486	but not death in COVID-19 positive but not negative cases. These medications are usually
487	prescribed to transplant recipients, who have been identified as being at higher risk for severe
488	COVID-19 [32]. A possible explanation for our findings is that patients on immune-suppressants
489	on average adopted precautions to avoid SARS-CoV-2 exposure, but once infected were more
490	likely to be hospitalized. The lack of significantly increased risk of death is an encouraging
491	finding.

492 **5. Conclusions**

- 493 In conclusion, our analysis of N3C enclave data suggests that patients on prescription non-
- 494 specific NSAIDs or celecoxib do not face increased risks of severe outcomes in COVID-19, with
- the possible exception of patients on aspirin. Celecoxib was associated with decreased risk of
- 496 mortality in both COVID-negative and COVID-positive cases. Unvaccinated patients on chronic
- 497 systemic steroids and particularly immune-suppressive medications may face increased risk of
- 498 severe COVID-19 outcomes. Our data do not support the notion that background treatment
- 499 with antidepressants or fluvoxamine affect COVID-19 outcomes in the patient categories we
- 500 studied.

502 Acknowledgements

- 503 National COVID Cohort Collaborative (N3C) Consortium membership includes:
- 504 1. Christopher G. Chute
- 505 Johns Hopkins University
- 506 ORCID: 0000-0001-5437-2545
- 507 chute@jhu.edu
- 508 Contributions: clinical data model expertise, data curation, data integration, data quality
- 509 assurance, data security, funding acquisition, governance, N3C Phenotype definition, project
- 510 evaluation, project management, and regulatory oversight/admin.
- 511 Individual Acknowledgements for Core Contributors
- 512 We gratefully acknowledge the following core contributors to N3C: Adam B. Wilcox, Adam M.
- 513 Lee, Alexis Graves, Alfred (Jerrod) Anzalone, Amin Manna, Amit Saha, Amy Olex, Andrea Zhou,
- 514 Andrew E. Williams, Andrew M. Southerland, Andrew T. Girvin, Anita Walden, Anjali
- 515 Sharathkumar, Benjamin Amor, Benjamin Bates, Brian Hendricks, Brijesh Patel, G. Caleb
- 516 Alexander, Carolyn T. Bramante, Cavin Ward-Caviness, Charisse Madlock-Brown, Christine
- 517 Suver, Christopher G. Chute, Christopher Dillon, Chunlei Wu, Clare Schmitt, Cliff Takemoto, Dan
- 518 Housman, Davera Gabriel, David A. Eichmann, Diego Mazzotti, Donald E. Brown, Eilis Boudreau,
- 519 Elaine L. Hill, Emily Carlson Marti, Emily R. Pfaff, Evan French, Farrukh M Koraishy, Federico
- 520 Mariona, Fred Prior, George Sokos, Greg Martin, Harold P. Lehmann, Heidi Spratt, Hemalkumar
- 521 B. Mehta, J.W. Awori Hayanga, Jami Pincavitch, Jaylyn Clark, Jeremy Richard Harper, Jessica
- 522 Yasmine Islam, Jin Ge, Joel Gagnier, Johanna J. Loomba, John B. Buse, Jomol Mathew, Joni L.
- 523 Rutter, Julie A. McMurry, Justin Guinney, Justin Starren, Karen Crowley, Katie Rebecca Bradwell,

524	Kellie M. Walters, Ken Wilkins, Kenneth R. Gersing, Kenrick Cato, Kimberly Murray, Kristin
525	Kostka, Lavance Northington, Lee Pyles, Lesley Cottrell, Lili M. Portilla, Mariam Deacy, Mark M.
526	Bissell, Marshall Clark, Mary Emmett, Matvey B. Palchuk, Melissa A. Haendel, Meredith Adams,
527	Meredith Temple-O'Connor, Michael G. Kurilla, Michele Morris, Nasia Safdar, Nicole Garbarini,
528	Noha Sharafeldin, Ofer Sadan, Patricia A. Francis, Penny Wung Burgoon, Philip R.O. Payne,
529	Randeep Jawa, Rebecca Erwin-Cohen, Rena C. Patel, Richard A. Moffitt, Richard L. Zhu,
530	Rishikesan Kamaleswaran, Robert Hurley, Robert T. Miller, Saiju Pyarajan, Sam G. Michael,
531	Samuel Bozzette, Sandeep K. Mallipattu, Satyanarayana Vedula, Scott Chapman, Shawn T.
532	O'Neil, Soko Setoguchi, Stephanie S. Hong, Steven G. Johnson, Tellen D. Bennett, Tiffany J.
533	Callahan, Umit Topaloglu, Valery Gordon, Vignesh Subbian, Warren A. Kibbe, Wenndy
534	Hernandez, Will Beasley, Will Cooper, William Hillegass, Xiaohan Tanner Zhang. Details of
535	contributions available at covid.cd2h.org/core-contributors.
536	The authors received direct benefit from discussions and presenting the project to the N3C –
537	Rural Health Domain teams. The authors would like to thank Sharon Patrick and the West
538	Virginia Clinical and Translational Science Institute (WVCTSI) for project planning and
539	management.

540 **References**

Vollbracht C, Kraft K. Oxidative Stress and Hyper-Inflammation as Major Drivers of
 Severe COVID-19 and Long COVID: Implications for the Benefit of High-Dose Intravenous
 Vitamin C. Front Pharmacol. 2022;13:899198. Epub 20220429. doi:

544 10.3389/fphar.2022.899198. PubMed PMID: 35571085; PubMed Central PMCID:

545 PMCPMC9100929.

546 2. Montazersaheb S, Hosseiniyan Khatibi SM, Hejazi MS, Tarhriz V, Farjami A, Ghasemian

547 Sorbeni F, et al. COVID-19 infection: an overview on cytokine storm and related interventions.

548 Virol J. 2022;19(1):92. Epub 20220526. doi: 10.1186/s12985-022-01814-1. PubMed PMID:

549 35619180; PubMed Central PMCID: PMCPMC9134144.

550 3. Eskandarian Boroujeni M, Sekrecka A, Antonczyk A, Hassani S, Sekrecki M, Nowicka H, et

al. Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19:

552 Targeting STATs as a Novel Therapeutic Strategy. Front Immunol. 2022;13:888897. Epub

553 20220517. doi: 10.3389/fimmu.2022.888897. PubMed PMID: 35663932; PubMed Central

554 PMCID: PMCPMC9156796.

555 4. Bahmani M, Chegini R, Ghanbari E, Sheykhsaran E, Shiri Aghbash P, Leylabadlo HE, et al.

556 Severe acute respiratory syndrome coronavirus 2 infection: Role of interleukin-6 and the

557 inflammatory cascade. World J Virol. 2022;11(3):113-28. doi: 10.5501/wjv.v11.i3.113. PubMed

558 PMID: 35665236; PubMed Central PMCID: PMCPMC9150027.

559 5. Newell KL, Waickman AT. Inflammation, immunity, and antigen persistence in post-

acute sequelae of SARS-CoV-2 infection. Curr Opin Immunol. 2022;77:102228. Epub 20220524.

561 doi: 10.1016/j.coi.2022.102228. PubMed PMID: 35724449; PubMed Central PMCID:

562 PMCPMC9127180.

563 6. Group WHOREAFC-TW, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, et al.

564 Association Between Administration of Systemic Corticosteroids and Mortality Among Critically

565 Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020;324(13):1330-41. doi:

566 10.1001/jama.2020.17023. PubMed PMID: 32876694; PubMed Central PMCID:

- 567 PMCPMC7489434.
- 568 7. Zhang W, Qin C, Fei Y, Shen M, Zhou Y, Zhang Y, et al. Anti-inflammatory and immune
- therapy in severe coronavirus disease 2019 (COVID-19) patients: An update. Clin Immunol.
- 570 2022;239:109022. Epub 20220425. doi: 10.1016/j.clim.2022.109022. PubMed PMID: 35477027;
- 571 PubMed Central PMCID: PMCPMC9040414.
- 572 8. Micallef J, Soeiro T, Jonville-Bera AP, French Society of Pharmacology T. Non-steroidal
- 573 anti-inflammatory drugs, pharmacology, and COVID-19 infection. Therapie. 2020;75(4):355-62.
- 574 Epub 20200507. doi: 10.1016/j.therap.2020.05.003. PubMed PMID: 32418728; PubMed Central
- 575 PMCID: PMCPMC7204680.
- 576 9. Eteraf-Oskouei T, Najafi M. The relationship between the serotonergic system and
- 577 COVID-19 disease: A review. Heliyon. 2022;8(5):e09544. Epub 20220526. doi:
- 578 10.1016/j.heliyon.2022.e09544. PubMed PMID: 35652122; PubMed Central PMCID:
- 579 PMCPMC9132783.
- 580 10. Haendel MA, Chute CG, Bennett TD, et al. The National COVID Cohort Collaborative
- 581 (N3C): Rationale, design, infrastructure, and deployment. J Am Med Inform Assoc.
- 582 2021;28(3):427-443. doi:10.1093/jamia/ocaa196
- 583 11. Reese JT, Coleman B, Chan L, Blau H, Callahan TJ, Cappelletti L, et al. NSAID use and
- 584 clinical outcomes in COVID-19 patients: a 38-center retrospective cohort study. Virol J. 2022
- 585 May 15;19(1):84. doi: 10.1186/s12985-022-01813-2. PMID: 35570298; PMCID: PMC9107579.

586 12. Quan-Charlson paper here: Quan H, Li B, Couris CM, et al. Updating and validating the

- 587 Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using
- 588 data from 6 countries. Am J Epidemiol. 2011;173(6):676-682. doi:10.1093/aje/kwq433
- 589 13. Danziger-Isakov L, Blumberg EA, Manuel O, Sester M. Impact of COVID-19 in solid organ
- transplant recipients. Am J Transplant. 2021;21(3):925-37. Epub 20210226. doi:
- 591 10.1111/ajt.16449. PubMed PMID: 33319449; PubMed Central PMCID: PMCPMC9800718.
- 592 14. Nso N, Nassar M, Zirkiyeva M, Mbome Y, Lyonga Ngonge A, Badejoko SO, et al. Factors
- 593 Impacting Stent Thrombosis in Patients With Percutaneous Coronary Intervention and Coronary
- 594 Stenting: A Systematic Review and Meta-Analysis. Cureus. 2022;14(4):e23973. Epub 20220409.

doi: 10.7759/cureus.23973. PubMed PMID: 35547463; PubMed Central PMCID:

596 PMCPMC9089933.

597 15. Borton ZM, Bhangoo NS, Quah CS, Stephen AB, Howard PW. Aspirin monotherapy is a

suitable standard thromboprophylactic agent following total hip arthroplasty. Hip Int.

599 2022;32(3):286-90. Epub 20210218. doi: 10.1177/1120700021990544. PubMed PMID:

600 33601921.

601 16. Ipema J, Brand AR, GJ DEB, JP DEV, Unl UC. Antiplatelet and anticoagulation therapy

after revascularization for lower extremity artery disease: a national survey and literature

603 overview. J Cardiovasc Surg (Torino). 2021;62(1):59-70. Epub 20201028. doi: 10.23736/S0021-

604 9509.20.11402-2. PubMed PMID: 33112125.

17. Ujjawal A, Gupta M, Ghosh RK, Jain V, Bandyopadhyay D, Qamar A, et al. Aspirin for

606 Primary Prevention of Coronary Artery Disease. Curr Probl Cardiol. 2021;46(3):100553. Epub

607 20200214. doi: 10.1016/j.cpcardiol.2020.100553. PubMed PMID: 32222319.

608	18.	Vasudeva R	, Challa A	, Al Rifai M	, Polana T	, Duran B	, Vindhy	/al M	, et al. Prevalence of
						, ,			/

- 609 cardiovascular diseases in COVID-19 related mortality in the United States. Prog Cardiovasc Dis.
- 610 2022;74:122-6. Epub 20221021. doi: 10.1016/j.pcad.2022.09.002. PubMed PMID: 36279944;
- 611 PubMed Central PMCID: PMCPMC9585886.
- 612 19. Baghaki S, Yalcin CE, Baghaki HS, Aydin SY, Daghan B, Yavuz E. COX2 inhibition in the
- 613 treatment of COVID-19: Review of literature to propose repositioning of celecoxib for
- randomized controlled studies. Int J Infect Dis. 2020;101:29-32. Epub 20200930. doi:
- 615 10.1016/j.ijid.2020.09.1466. PubMed PMID: 33007455; PubMed Central PMCID:
- 616 PMCPMC7525269.
- 617 20. Ghaznavi H, Mohammadghasemipour Z, Shirvaliloo M, Momeni MK, Metanat M,
- 618 Gorgani F, et al. Short-term celecoxib (celebrex) adjuvant therapy: a clinical trial study on
- 619 COVID-19 patients. Inflammopharmacology. 2022;30(5):1645-57. Epub 20220714. doi:
- 620 10.1007/s10787-022-01029-4. PubMed PMID: 35834150; PubMed Central PMCID:
- 621 PMCPMC9281238.
- 622 21. Liao Y. Identification of potential new COVID-19 treatments via RWD-driven drug
- 623 repurposing. Sci Rep. 2023;13(1):14586. Epub 20230904. doi: 10.1038/s41598-023-40033-8.
- 624 PubMed PMID: 37666866; PubMed Central PMCID: PMCPMC10477169.
- 625 22. Hsieh K, Wang Y, Chen L, Zhao Z, Savitz S, Jiang X, et al. Drug repurposing for COVID-19
- using graph neural network and harmonizing multiple evidence. Sci Rep. 2021;11(1):23179.
- 627 Epub 20211130. doi: 10.1038/s41598-021-02353-5. PubMed PMID: 34848761; PubMed Central
- 628 PMCID: PMCPMC8632883.

- 629 23. Gimeno A, Mestres-Truyol J, Ojeda-Montes MJ, Macip G, Saldivar-Espinoza B, Cereto-
- 630 Massague A, et al. Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2
- through Consensus Docking and Drug Reposition. Int J Mol Sci. 2020;21(11). Epub 20200527.
- doi: 10.3390/ijms21113793. PubMed PMID: 32471205; PubMed Central PMCID:
- 633 PMCPMC7312484.
- 634 24. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol.
- 635 2012;188(1):21-8. doi: 10.4049/jimmunol.1101029. PubMed PMID: 22187483; PubMed Central
- 636 PMCID: PMCPMC3249979.
- 637 25. Obeid S, Libby P, Husni E, Wang Q, Wisniewski LM, Davey DA, et al. Cardiorenal risk of
- 638 celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the
- 639 PRECISION trial. Eur Heart J Cardiovasc Pharmacother. 2022;8(6):611-21. doi:
- 640 10.1093/ehjcvp/pvac015. PubMed PMID: 35234840.
- 641 26. Liu B, Qu L, Yan S. Cyclooxygenase-2 promotes tumor growth and suppresses tumor
- 642 immunity. Cancer Cell Int. 2015;15:106. Epub 20151105. doi: 10.1186/s12935-015-0260-7.
- 643 PubMed PMID: 26549987; PubMed Central PMCID: PMCPMC4635545.
- 644 27. Jin K, Qian C, Lin J, Liu B. Cyclooxygenase-2-Prostaglandin E2 pathway: A key player in
- tumor-associated immune cells. Front Oncol. 2023;13:1099811. Epub 20230127. doi:
- 646 10.3389/fonc.2023.1099811. PubMed PMID: 36776289; PubMed Central PMCID:
- 647 PMCPMC9911818.
- 648 28. Ye SY, Li JY, Li TH, Song YX, Sun JX, Chen XW, et al. The Efficacy and Safety of Celecoxib in
- 649 Addition to Standard Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized
- 650 Controlled Trials. Curr Oncol. 2022;29(9):6137-53. Epub 20220825. doi:

651 10.3390/curroncol29090482. PubMed PMID: 36135051; PubMed Central PMCID:

- 652 PMCPMC9497539.
- 653 29. Patrono C. Cyclooxygenase Inhibitors and Cancer: The Missing Pieces. J Pharmacol Exp

654 Ther. 2023;386(2):181-9. Epub 20230606. doi: 10.1124/jpet.122.001631. PubMed PMID:

- 655 37280092.
- 656 30. Rashid G, Khan NA, Elsori D, Rehman A, Tanzeelah, Ahmad H, et al. Non-steroidal anti-
- 657 inflammatory drugs and biomarkers: A new paradigm in colorectal cancer. Front Med
- 658 (Lausanne). 2023;10:1130710. Epub 20230306. doi: 10.3389/fmed.2023.1130710. PubMed
- 659 PMID: 36950511; PubMed Central PMCID: PMCPMC10025514.
- 660 31. Newman P, Muscat J. Potential Role of Non-Steroidal Anti-Inflammatory Drugs in
- 661 Colorectal Cancer Chemoprevention for Inflammatory Bowel Disease: An Umbrella Review.
- 662 Cancers (Basel). 2023;15(4). Epub 20230209. doi: 10.3390/cancers15041102. PubMed PMID:
- 663 36831446; PubMed Central PMCID: PMCPMC9954537.
- 664 32. Gadi V, Shetty SR. Potential of Anti-inflammatory Molecules in the Chemoprevention of
- 665 Breast Cancer. Recent Adv Inflamm Allergy Drug Discov. 2022;16(2):60-76. doi:
- 666 10.2174/2772270816666220829090716. PubMed PMID: 36043708.
- 667 33. Abdelhaleem EF, Kassab AE, El-Nassan HB, Khalil OM. Recent advances in the
- 668 development of celecoxib analogs as anticancer agents: A review. Arch Pharm (Weinheim).
- 669 2022;355(12):e2200326. Epub 20220822. doi: 10.1002/ardp.202200326. PubMed PMID:
- 670 35996360.
- 671 34. El-Malah AA, Gineinah MM, Deb PK, Khayyat AN, Bansal M, Venugopala KN, et al.
- 672 Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing.

- 673 Pharmaceuticals (Basel). 2022;15(7). Epub 20220703. doi: 10.3390/ph15070827. PubMed
- 674 PMID: 35890126; PubMed Central PMCID: PMCPMC9318302.
- 675 35. Eyitemi J, Thomas B, Ramos Y, Feng X, Ezekwesili C. SARS-CoV-2: Review of Conditions
- Associated With Severe Disease and Mortality. Int J Prev Med. 2022;13:109. Epub 20220808.
- doi: 10.4103/ijpvm.IJPVM_640_20. PubMed PMID: 36247195; PubMed Central PMCID:
- 678 PMCPMC9564226.
- 679 Supporting information
- 680 S1 Supplemental Material









results.

A1 (all medication A users)

A2 (medication A users who develop COVID)

> A3 (medication A users with COVID diagnoses)

> > A4 (Hospitalizations for COVID)

> > > A5 (COVID deaths within 90

days)



	Measure M1			Measure M2				Measure M3			
Med group A	samplesize	aOR_ pvalue	2	samplesize	aOR_	pvalue		samplesize	aOR_	pvalue	
NSAIDs	2653/1519	0.51 <0.00	-=-	2653/1519	0.79	0.002		429/447	0.74	0.2	
celecoxib aspirin	2716/1519	0.32 0.03 1.32 0.024	+	2716/1519	1.62	<0.001	•	40/447	0.14	0.060	·
imm.suppressants	384/1519	1.13 0.0	; <u> </u>	384/1519	1.86	<0.001	+	; 194/447	1.15	0.6	-
steroid	5885/1519	1.15 0.3	2 +	5885/1519	1.33	<0.001	•	2111/447	1.23	0.2	
antidepressants	2885/1519	0.93 0.9	5 -	2885/1519	1.1	0.2	•	832/447	1.01	>0.9	
			0.10 0.20 0.50 1.0 2.0 4.0				0.30 0.20 0.50 1.0 2.0 4.0				0.10 0.20 0.50 1.0 2.0 4.0
		Measure M5				Measure M6					
Med group A	samplesize	aOR_ pval	Je .	samplesize	aOR_	pvalue		samplesize	aOR_	pvalue	
NSAIDs	8451/4827	0.25 <0.00)1	8451/4827	0.78	<0.001		5603/4911	0.34	<0.001	
celecoxib	1309/4827	0.11 <0.00	01 -	1309/4827	0.95	0.5	+	1719/4911	0.21	< 0.001	
aspirin	7629/4827	0.86 0.3	.0 -	7629/4827	1.17	0.001		11081/4911	0.66	<0.001	
imm.suppressants	622/4827	0.37 <0.00	01 —	622/4827	0.92	0.4	+	: 661/4911	0.49	<0.001	+
steroid	15848/4827	0.77 0.00)1 •	15848/4827	1.26	< 0.001		18776/4911	0.79	<0.001	
antidepressants	7106/4827	0.65 <0.00)1 🛥	7106/4827	0.93	0.12		6291/4911	0.67	<0.001	
			0.10 0.20 0.50 1.0 2.0 4.0				020 020 030 10 20 40				010 020 030 10 20 40

M1, M2, and M3 are the adjusted aOR values comparing **90-day death rates**, **90-day admission rates**, and **death rate among hospitalized patients** for COVID positive subjects. M4, M5, and M6 are the adjusted aOR values comparing **90-day death rates**, **90-day admission rates**, and **death rate among hospitalized patients** for COVID negative subjects.

Each adjusted odds ratio (aOR) in the figure is an estimate medication effect from one model – adjusted for demographics, Charlson Comorbidity Index, with data partner as a random effect.



Numbers above bars are pvalues for difference in the two relative risk values.



Lower curve: Measure M1 values from primary analysis. Upper curve: Measure M1 values after adjustment for unknown covariates. Middle curve: Measure M1 values with indirect medication effects removed.